Viseon

About Viseon

Viseon, Inc. operates as a medical device company focused on improving intraoperative visualization for minimally invasive surgery (MIS) and open procedures. Established in 2017 by founders Lisa Zindel and Alex Thomson, the Irvine, California-based firm develops single-use, 4K imaging technologies designed to provide surgeons with a clear, magnified view of the surgical site. The company was spun out from Rebound Therapeutics Corporation in early 2017.

The company's core business revolves around providing an alternative to traditional visualization tools like surgical microscopes, endoscopes, and loupes, which can be capital-intensive and cumbersome. Viseon targets hospitals and ambulatory surgical centers, offering a system that projects high-definition images onto an operating room's flat-panel display. This approach allows the entire surgical team, including trainees, to view the procedure in real-time, enhancing collaboration, training, and workflow efficiency. Its business model focuses on the sale of these single-use, disposable visualization systems, which helps medical facilities avoid the large upfront costs and ongoing maintenance associated with reusable equipment.

Viseon's flagship product line, including the MaxView® and Voyant™ Systems, provides surgeons with 4K resolution imaging. These systems are designed to be low-profile and integrate with existing surgical retractors, particularly for spinal procedures. Key features include the ability to capture and record 4K video and still images for documentation, patient education, and building a digital library for future analysis, potentially with machine learning and AI. The company received its first FDA 510(k) clearance in October 2018 for the Voyant System for use in minimally invasive spine surgery. Initially concentrating on the spine market—including posterior, lateral, and cervical applications—Viseon has since announced plans to expand into other surgical fields. The company has demonstrated market traction, reporting over 30% sales growth in 2023 and the completion of over 1,000 procedures with its MaxView system by May 2022.

The company is privately held and venture capital-backed, having raised a total of $52.7M. A significant Series B funding round of $29.4 million was completed in February 2020, with investors including Invus, Wexford Capital LP, and HBM-MedFocus. This funding was aimed at supporting product development, regulatory approvals, and commercialization efforts. Another insider financing round was completed in June 2024 to fund further development and market expansion.